Background and aim: the standard of care therapy for chronic hepatitis C with imported Peginterferon alpha (PegIFN) plus ribavirin has high cost, many patients cannot approach. Recently, NANOGEN Biophannaceutical company in Viet Nam has produced PegIFN alpha-2a under the trademark of Pegnano and Dong Nam pharmaceutical company producing ribavirin (Barivir) with the market price cheaper than imported drugs nearly 2.5 times. The aim of study was to determine the efficacy of combining Pegnano plus Barivir in treatmentnaive patients with chronic hepatitis C. Methods: uncontrolled clinical trial was conducted at Kien Giang general hospital between 3/2011- 3/2012. One hundred patients with chronic hepatitis C were treated with Pegnano 180 mcg/week plus Barivir 15 mg/Kg/day during 24 weeks or 48 weeks depending on genotype and viral response. Viral responses and adverse drug reactions were recorded periodically. Results: eighty-six cases ended up treatment with 58 percent genotype 6.27 percent genotype 1 and 15 percent genotype 2. Discontinuation of therapy occurred in 2.4 percent due to adverse events and 1.2 percent due to viral breakthrough. End of treatment response rate was 97 percent. Twelve cases with genotype 2 completed mon itoring phase after treatment with sustained viral response rate was 83 percent. Adverse events leading to dose reduction of Pegnano due to thrombocytopenia was 8 percent, neutropenia was 1.2 percent and moderate depression was 3.5 percent. Dose reduction of Barivir due to anemia was 27 percent. Thyroid dysfunction wqs 6 percent. Conclusions: preliminary results of treatment of chronic hepatitis C with Pegnclno plus Barivir showed the rate of end of treatment response high, the rate of sustained vital response of cases with genotype 2 equivalent with the rate of previous reports treating with imported drugs, adverse events generally in the range accepted and tolerability.
- Đăng nhập để gửi ý kiến